Furthermore, due to its anti-apoptotic and pro-“stemness” functions, JAG1 blockade represents an attractive option also for combination therapy approaches with standard chemotherapy as demonstrated in preclinical models of ovarian and pancreatic cancer and lymphoma (19, 39, 69). Here, JAG1 is linked to pancreatic neoplasm.